Cafepharma Today

June 5 2025 - GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
Bispecific cancer drugs, data caveats and funding alarms: 3 takeaways from ASCO
FDA’s Elsa AI is here, and the industry has questions
Merck gains U.S. patent office support in Keytruda dispute
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Allergan, Actavis Top Big Cap Pharmas Amid M&A Flurry
Investors.com
Wednesday, June 18, 2014 - 10:33am
tags:
Valeant Pharmaceuticals, M&A, Actavis, Allergan
New Alkermes Schizophrenia Drug -- An Important Advance With Social Benefits
Forbes
Wednesday, June 18, 2014 - 10:11am
tags:
aripiprazole lauroxil, schizophrenia, Alkermes
Novartis overhaul expected to improve core operating income margin
The Fly on the Wall
Wednesday, June 18, 2014 - 10:07am
tags:
reorganization, Novartis Business Services, Novartis
Vertex Licenses VX-787 to Janssen Pharmaceuticals for the Treatment of Influenza
Yahoo/BusinessWire
Wednesday, June 18, 2014 - 9:27am
tags:
VX-787, Vertex Pharmaceuticals, Janssen
Zalicus Licenses Sodium Channel Pain Modulation Program
Yahoo/BusinessWire
Wednesday, June 18, 2014 - 8:39am
tags:
Zalicus, pain management, AnaBios
Cara Therapeutics Initiates Phase Ia/Ib Trial of Tablet Formulation of Oral CR845 for the Treatment of Acute and Chronic Pain
Yahoo/Globe Newswire
Wednesday, June 18, 2014 - 8:37am
tags:
pain management, CR845, Cara Therapeutics
Protalix BioTherapeutics Initiates Phase II Study With PRX-112, an Orally-Administered Enzyme Replacement Therapy for the Treatment of Gaucher Disease
Yahoo/Globe Newswire
Wednesday, June 18, 2014 - 8:36am
tags:
PRX-112, Protalix BioTherapeutics, Gaucher disease
Expecting hostile suitors, Shire brings in reinforcements
Fierce Pharma
Wednesday, June 18, 2014 - 5:31am
tags:
Shire, M&A, Bristol-Myers Squibb, Amgen, AbbVie, Gilead Sciences, Biogen Idec
Analyst: GlaxoSmithKline's Tykerb dead in the water after breast cancer failure
Fierce Pharma
Wednesday, June 18, 2014 - 4:29am
tags:
GSK, Tykerb, breast cancer
IPO Preview: ZS Pharma
Seeking Alpha
Wednesday, June 18, 2014 - 4:25am
tags:
IPOs, ZS Pharma
IPO Preview: Parnell Pharmaceuticals Holdings
Seeking Alpha
Wednesday, June 18, 2014 - 4:24am
tags:
Parnell Pharmaceuticals, IPOs, animal health
Cipla’s Drug Pipeline Makes It $10 Billion Prey: Real M&A
Bloomberg
Wednesday, June 18, 2014 - 4:23am
tags:
Cipla, M&A, India, Mylan, Teva Pharmaceuticals
Pfizer signs cancer immunotherapy deal with France's Cellectis
Yahoo/Reuters
Wednesday, June 18, 2014 - 4:22am
tags:
Pfizer, France, Cellectis, cancer immunotherapy
Responding to critics, Valeant CEO says company can grow organically
Marketwatch
Wednesday, June 18, 2014 - 4:21am
tags:
Valeant Pharmaceuticals, Allergan, M&A, J. Michael Pearson
Time Isn’t on Valeant’s Side in Allergan Bid
Barron's
Wednesday, June 18, 2014 - 4:20am
tags:
Valeant Pharmaceuticals, M&A, Allergan
Valeant Readies Hostile Exchange Offer for Allergan
TheStreet.com
Tuesday, June 17, 2014 - 7:07pm
tags:
hostile takeover, Valeant Pharmaceuticals, Allergan, M&A
Is This Gilead's Worst Nightmare?
Motley Fool
Tuesday, June 17, 2014 - 7:00pm
tags:
Gilead Sciences, Sovaldi, hepatitis C, Enanta Pharmaceuticals, AbbVie
Major pharmaceutical groups may be too big to succeed
FT.com
Tuesday, June 17, 2014 - 6:54pm
tags:
M&A, Pfizer, AstraZeneca
Glaxo's Promacta Holds Promise
Yahoo/Zacks.com
Tuesday, June 17, 2014 - 6:50pm
tags:
GSK, Promacta, chronic immune thrombocytopenic purpura
[video] Medical Marijuana Industry Revenue Could Reach $8.4 Billion
TheStreet.com
Tuesday, June 17, 2014 - 6:14pm
tags:
Medical Marijuana

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Not One of Your Easy Crystals
In the Pipeline
The Continuing Crisis, Part XV: The Horrendous Trump Budget
In the Pipeline
Taurine Revisited
In the Pipeline
A New Route to Asthma Treatment - Through the Liver, of All Places
In the Pipeline
One Drug's Supply Chain, In Detail
In the Pipeline
A Reaction to Alzheimer's Fraud
In the Pipeline
Whoa Now: Cautionary Tales from Materials Science
In the Pipeline
Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.